Exhibit 99.1

Senior Scientist Anthon y Oliva , PhD Director of Patient & Clinical Services Jessic a Protenic , B.S.N. , R.N. International E x ecutive Director P a u l T . L e h r , J . D . Associate Directo r , Medical A f airs K ev i n N . R a m d a s , M . D . , M . P . H . May 2021 Lon g e v e r on Inc. UPD A TE S I N CEL L THERAP Y AN D HEA L TH Y AGING L E D G E R I n T hi s Is sue ■ Treatments for Alzheimer’s Disease and Related Dementia s – L o n g e v er o n A nn o un c e s P o s i t i v e R e s u l t s o f P h a s e I C li n i c a l S t ud y o f L o m e c e l - B Cel l Therap y fo r Alzheimer ’ s Disease ■ L o n g e v er on ’ s U . S . C li n i c a l T r i a l s U pd a t e ■ Longeveron’s Foreign Trials/Registry Update ■ Ho w Doe s L ongevero n Ge t It s Bon e Marro w & M ak e I t s P r o du c t ? ■ M e d i c i n a l S i g n a li n g C e ll s – P o ss i b l e B e n e f i t s f o r Spina l Cor d Injur y & S tro k e ■ L o n g e v er o n A nn o un c e s P r i c i n g o f a n U p s i z e d $26.6 Million Initial Public O f ering & NASDAQ Listing

Treatments for Alzheimer’s Disease and Related Dementias – Lon g e v e r o n Announ c e s P ositi v e Results of Phase I Clinical Study of Lomecel - B Cell Therapy for Alzheimer’s Disease Fifty million people worldwide currently have dementia, which is a progressive decline in cognitive functioning that can interfere with daily activities, and eventually lead t o a lo s s o f i n d e p e n d e n c e a n d d e a t h o v e r t h e c o u r s e o f years. The most common form of dementia is Alzheimer’s disease. Scientists have found abnormal proteins in the brain of patients with Alzheimer’s disease. These abnormal proteins deposit in the brain tissue itself and can interfere w i t h t h e n o r m a l f un c t io n i n g o f t h e b r a i n . S o m e e a r ly s i g ns of Alzheimer’s disease may include: memory loss; confusion about time and places; impaired problem solving and planning abilities; di ffi culty with speaking, writing clearly and completing familiar tasks; impaired ability to understand visual ex99-1_s and spatial relationships; and mood or personality changes. In the US alone, approximately 5.4 million people su ff er from Alzheimer’s disease, and this number is projected to increase to 14 million by 2050 accordin g t o th e Alzheimer ’ s Association , a leadin g non - profit organization for dementia research. The cost of care for these patients is already stressing healthcare systems, not to mention the enormous toll it takes on families and care - givers. There is thus an urgent need for e ff ective treatments for A l z h e i m e r’ s d i s e a s e a n d r e l a t e d d e m e n t i a s . H o w e v e r , t h e r e ar e currentl y n o approve d medication s tha t ca n slow - down , stop , o r revers e th e pr o g r e ss i o n o f A l z h e i m e r ’ s disease . O n ly f i v e m e d i c a t io n s h a v e r e c e i v e d FD A a pp r o v a l for Alzheimer’s disease, and none significantly alter the course of disease progression. Three of these (donepezil, galantamine and rivastigmine) fall into a class of drugs called “cholinesterase inhibitors,” and another, memantine, is in a class of drugs called “NMDA receptor antagonists.” All four of these work by altering the communication between the cells of the brain (these are called neurons). The fifth medication is a combination of two of these drugs (donepezi l an d memantine). With the exception of the above five drugs (which do not appear to ameliorate disease progression), we have witnessed decades of failed attempts to develop small molecule drugs for treating Alzheimer’s disease. At Longeveron, we hope that an alternative approach using regenerative medicine may provide a much needed solution for combating this devastating disease. Medicinal Signaling Cells (MSCs) have numerous mechanisms of action that may potentially impact the complex pathology associated w i t h A l z h e i m e r’ s d i s e a s e . B e y o n d t h e h a ll m a r k s o f t h e a b n o r m a l p r o t e i n s , w h i c h c a n d e p o s i t i n a r e a s of the brain or “plaques”, Alzheimer’s disease is also characterized by inflammation in the brain (referred to as “neuroinflammation”), poor functioning of the blood vessels of the brain (“neurovasculature dysfunction”), and degeneration of brain cells (“neurodegeneration”), among o t h e r f e a t u r e s . M S C s c a n p o t e n t i a lly h a v e a n e f f e c t o n a l l of these aspects of Alzheimer’s disease, and preclinical studie s suppor t thi s conclusio n [1 - 9] . Us i n g m o u s e m o d e l s o f Alzheimer’s disease, MSCs decreased inflammation in the brain, promoted break - down and clearance of the abnormal proteins deposited in the brain, promoted new nerve cell formatio n (“neurogenesi s ”) , an d improve d th e cognitive/ behaviora l performanc e o f th e mic e . I n additio n when M S C s w e r e g i v e n t o y o un g e r a n i m a l s t h e y p r e v e n t e d t h e development of the abnormalities in the brains. Longeveron recently completed a Phase 1 clinical trial to evaluate the safety and gain preliminary information about the potential e ffi cacy of its MSC product, called Lomecel - B (formerly referred to as Longeveron Mesenchymal Stem Cells, or LMSCs), for Alzheimer’s disease. This randomized, placebo - controlled study was funded in part by the Alzheimer’s Association. A total of 33 subjects with mild Alzheimer’s disease participated in this Phase 1 stud y . Each subject was randomly assigned to a group and received a single infusion of low - dose or high - dose Lomecel - B, or placebo in a double - blinded manner (meaning that neither the subjects nor clinical sta ff knew which intervention each subject received). This Phase I trial met its primary safety endpoint, which paves the way for future trials in subjects with Alzheimer’s disease. Importantly, several pre - specified secondary e ffi cacy endpoints and biomar k er results support potential benefit from Lomecel - B. The study results provide support for the theory that Lomecel - B can potentially reduce Alzheimer’s disease associated brain inflammation, improve function of blood vessels in the brain, reduce brain damage due to Alzheimer’s disease progression, and promote regenerative responses. Key findings from new and previously disclosed data: ■ Lomecel - B infusion was well - tolerated in this trial, with no treatment - related serious adverse events observed throughout the 1 - year follow - up, including no indications of amyloid - related imaging abnormalities (ARIA) as assessed by magnetic resonance imaging (MRI); ■ The average Mini Mental State Exam (MMSE) score, which is a measure of cognitive function declined

more slowly in the low - dose Lomecel - B group compared to the placebo grou p . A t 13 wee k s after infusion, the low - dose L omecel - B group MMSE score was higher (better) compared to placebo (di ff erence of 2.69 “ 1.39 points; p=0.0182; 2 - sided 95% CI 0.51 – 4.97); ■ At 26 weeks post - infusion, patients in the low - dose Lomecel - B arm showed a significantly higher (better) average score on the Quality of Life in Alzheimer Disease (QOL - AD) compared to placebo (di ff erence of 3.85 “ 1.943 points; p= 0 .0444; 2 - sided 95% CI 0 . 13 – 9 . 12); ■ At 26 weeks post - infusion, the Alzheimer’s Disease Cooperative Study Activities of Daily Living (ADCS - ADL), a measure of competence in basic and instrumental activities of daily living, was significantly higher (better) in the low - dose Lomecel - B group compared to placebo (di ff erence of 6.95 “ 3.46 points; p= 0 .0118; 95% CI 1.99 – 13.94); Biomarkers: ■ Subjects receiving Lomecel - B had significantly increased serum levels of several provascular biomar k ers (VEG F , IL 4 , and IL - 6 ) relative to the placebo group post - infusion. ■ There was a significant increase in D - dimer in the high - dose, but not low - dose, Lomecel - B arm versus placebo; ■ Subjects receiving Lomecel - B had significantly increased serum levels of several anti - inflammatory cytokines (sIL - 2R α , IL - 4, IL - 10 and IL - 12) relative to the placebo group postinfusion; ■ There were no significant changes in the Lomecel - B arms versus the change in placebo for any of neuronal - related biomarkers examined; ■ MRIs showed a significant increase in change in left hippocampus volume in the high - dose Lomecel - B arm versus the change in placebo group at Week 13 (p=0.0311). By Week 26, the di ff erence was no longer significant. The low dose Lomecel - B arm showed no significant di ff erence versus placebo. The complete trial results are currently being prepared for publication in a peer - review journal, and results detailed above are posted in a press release on the company’s website, www.longeveron.com. Longeveron plans to use proceeds from its IPO to start a larger Phase II trial in the second half of this year. References “Alzheimer’s Disease” 1. Kim S, Chang KA, Kim J, Park HG, Ra JC, Kim HS, et al. The preventive and therapeutic e ff ects of intravenous human adipose - derived stem cells in Alzheimer’s disease mice. PloS one. 2012;7(9):e45757. doi: 10.1371/journal.pone.0045757. PubMed PMID: 23049854; PubMed Central PMCID: PMC3458942. 2. Yang H, Yue C, Yang H, Xie Z, Hu H, Wei L, et al. Intravenous Administration of Human Umbilical Cord Mesenchymal Stem Cells Improves Cognitive Impairments and Reduces Amyloid - Beta Deposition in an AbetaPP/PS1 Transgenic Mouse Model. Neurochem Res. 2013. doi: 10.1007/s11064 - 013 - 1161 - 6. PubMed PMID: 24078266. 3. Kim KS, Kim HS, Park JM, Kim HW, Park MK, Lee HS, et al. Long - term immunomodulatory e ff ect of amniotic stem cells in an Alzheimer’s disease model. Neurobiol Aging. 2013;34(10):2408 - 20. doi: 10.1016/j.neurobiolaging.2013.03.029. PubMed PMID: 23623603. 4. Yang H, Yang H, Xie Z, Wei L, Bi J. Systemic transplantation of human umbilical cord derived mesenchymal stem cells - educated T regulatory cells improved the impaired cognition in AbetaPPswe/PS1dE9 transgenic mice. PloS one. 2013;8(7):e69129. doi: 10.1371/journal.pone.0069129. PubMed PMID: 23935936; PubMed Central PMCID: PMCPMC3723739. 5. Oh SH, Kim HN, Park HJ, Shin JY, Lee PH. Mesenchymal Stem Cells Increase Hippocampal Neurogenesis and Neuronal Di ff erentiation by Enhancing the Wnt Signaling Pathway in an Alzheimer’s Disease Model. Cell Transplant. 2015;24(6):1097 - 109. Epub 2014/03/13. doi: 10.3727/096368914X679237. PubMed PMID: 24612635. 6. Boutajangout A, Noorwali A, Atta H, Wisniewski T. Human Umbilical Cord Stem Cell Xenografts Improve Cognitive Decline and Reduce the Amyloid Burden in a Mouse Model of Alzheimer’s Disease. Curr Alzheimer Res. 2017;14(1):104 - 11. PubMed PMID: 27719629; PubMed Central PMCID: PMCPMC5241019. 7. Wei Y, Xie Z, Bi J, Zhu Z. Anti - inflammatory e ff ects of bone marrow mesenchymal stem cells on mice with Alzheimer’s disease. Exp Ther Med. 2018;16(6):5015 - 20. doi: 10.3892/etm.2018.6857. PubMed PMID: 30542456; PubMed Central PMCID: PMCPMC6257159. 8. Kim DH, Lim H, Lee D, Choi SJ, Oh W, Yang YS, et al. Thrombospondin - 1 secreted by human umbilical cord blood - derived mesenchymal stem cells rescues neurons from synaptic dysfunction in Alzheimer’s disease model. Sci Rep. 2018;8(1):354. doi: 10.1038/s41598 - 017 - 18542 - 0. PubMed PMID: 29321508; PubMed Central PMCID: PMCPMC5762817. 9. Ge M, Zhang Y, Hao Q, Zhao Y, Dong B. E ff ects of mesenchymal stem cells transplantation on cognitive deficits in animal models of Alzheimer’s disease: A systematic review and meta - analysis. Brain and Behavior. 2018;8(7):e00982. doi: 10.1002/brb3.982.

LONGEVERON’ S U.S. CLINI C A L TRIAL S UP D A TE Longeveron is conducting several clinical trials under FDA oversight to evaluate the clinical e f' ects of Longeveron’s Lomecel - B product. Lomecel - B is an allogeneic, bone marrow - derived medicinal signaling cell (MSC) product manufactured under current Good Manufacturing Practices (cGMP) in Longeveron’s cell processing facility in Miami, Florida. Longeveron currently has one clinical study ongoing, four completed and in the data collection and/or analysis phase, and three more studies expected to begin in 2021. These multi - center trials range from Alzheimer’s disease to Aging Frailty and other chronic disease indications. If you or someone you know may be interested in learning more about the trials, details can be found by typing “Longeveron” in the search bar on www.ClinicalTrials.gov. Completed – Phase 1 First - In - Human Clinical S t u d y o f L o m e c e l - B i n H y p o p l a s t i c L e f t H e a r t S y n d r o m e S u b j e c t s We have also completed our Phase 1 first - in - human clinical study of Lomecel - B in Hypoplastic Left Heart Syndrome (HLHS), a rare pediatric cardiac condition. The study of 10 trial subject babies was conducted by a consortium of leading pediatric cardiac surgeons at centers that included the University of Maryland Medical Center, University of Cincinnati/Children’s Hospital Medical Center and University of Utah Primary Children’s Hospital, and was supported in part by a Maryland Stem Cell Research Fund (MSCRF) TEDCO Grant. This study was designed to assess safety and tolerability of intramyocardial injection of Lomecel - B administered to 10 babies with HLHS during the Stage 2 b i d i r e c t io n a l c a v o p u l m o n a r y a n a s t o m o s i s ( BD C P A , o r “ G l e n n procedure”) surgery. HLHS is a rare congenital heart defect that e ff ects approximately 1,000 babies per year in the U.S. Babies with HLHS are born with an underdeveloped left ventricle, which impairs the heart’s ability to pump adequate amounts of blood throughout the body. Without a three - staged reconstructive surgery, the condition is often fatal. Even with surgery, HLHS is still associated with high mortality. The Phase 1 safety results h a v e e n a b l e d L o n g e v e r o n t o a d v a n c e i t s H L H S p r o g r a m i n t o a Phase 2 multi - center randomized, double - blind, placebo - controlled trial, which is scheduled to begin in the third quarter of 2021. The Phase 2 trial, which will study approximately 35 patients nationwide, is being funded by a grant from the National Institute of Health’s National Heart, Lung, and Blood Institute (NHLBI). C o m p l e t e d – P h a s e 2 b C l i n i c a l S t u d y o f L o m e c e l - B f o r A gi n g F r a i l t y S u b j e c t s We have completed our Phase 2b clinical study of a Lomecel - B infusion for Aging Frailty subjects. The multicenter study was conducted at various hospitals and clinics, primarily in South Florida, including the Miami VA Healthcare System, and was supported in part by a Small Business Administration (SBIR) grant from the NIH’s National Institute on Aging (NIA). It is anticipated that the top - line trial results will be announced in the 3rd q u a r t e r o f 2 0 2 1 . O n e - hun d r e d - a n d - f o r t y - n i n e t r i a l s u b j e c t s w e r e randomized to receive a single peripheral intravenous infusion of Lomecel - B at di ff erent doses (25 million, 50 million, 100 million or 200 million cells), or placebo, followed by a 1 - year observation period to evaluate safety and e ffi cacy. The primary objective of the study is to assess the e ff ect of Lomecel - B on exercise tolerance and endurance via the six - minute walk test. Additional endpoints include gait speed, grip strength, assessments for risk and fear of falling, depression, sexual function, cognition, various patient reported outcomes and activities of daily living, and blood - base d biomar k ers. Completed – Phase 1 Clinical Study of L o m e c e l - B f o r A lz h e i m e r ’ s D i s e a s e S u b j e c t s W e h a v e a l s o c o m p l e t e d o u r P h a s e 1 A l z h e i m e r’ s d i s e a s e ( A D ) trial designed to examine the safety of Lomecel - B on people i n th e earl y stage s o f A D (mil d AD) . Th e result s showe d that Lomecel - B was safe and well - tolerated in this study. Full results are currently being analyzed and a manuscript describing the m e t h o d s , r e s u l t s a n d c o n c l u s io n s a r e e x p e c t e d t o b e s u b m i tt e d for potential publication in a peer - reviewed journal. All Longeveron clinical trials in the United States referenced in this Longeveron Ledger have been listed in ClinicalTrials.gov and have been conducted under an FDA Investigational New Drug Application (IND).

LONGEVERON’S FOREIG N TRIALS/ REGIST R Y UP D A TE NA S S A U , B AHAMAS E n r o ll i n g – S i n g l e - A r m T r e a t m e n t Re gi s t r i e s o f L o m e c e l - B In 2017, Longeveron received approval from the National Stem Cell Ethics Committee (NSCEC) under the Bahamian Ministry of Health to have single - arm experimental Treatment Registries (i.e. there are no placebo or other treatment groups so every participant receives Lomecel - B) in Nassau, Bahamas, for the following conditions: ■ Aging Frailty (ages 50 - 95); ■ Frailty for reasons other than aging (ages 18 - 95) (e.g. from autoimmune issues, chronic Lyme Disease, Chronic Fatigue Syndrome); ■ Musculoskeletal Injury Due to Overuse or Athletics (ages 18 - 95); ■ Alzheimer’s Disease/Cognitive Impairment (ages 50 - unlimited); ■ Osteoarthritis (ages 18 - 95). [Current travel rules/restrictions into Nassau: Every traveler must receive a negative Covid - 19 RT - PCR and an approved Travel Visa from the Bahamian Ministry of Tourism website travel.gov.bs] T O K Y O , J A P A N A pp r o v e d – P h a s e 2 C l i n i c a l S t u d y o f L o m e c e l - B f o r A gi n g F r a i l t y S u b j e c t s A Phase 2, investigator - sponsored clinical trial has b ee n a pp r o v e d b y J a p a n ’ s P h a r m a c e u t i c a l a n d Medical Devices agency (PMDA) intended to evaluate th e safet y an d e ffi cac y o f L omecel - B infusio n in Japanese Aging Frailty subjects. The planned study is a 45 - subject randomized, double - blind, placebo - controlled trial, and it is anticipated that the clinical sites will be Juntendo University Hospital and the National Center for Geriatrics and Gerontology (NCGG). This trial is expected to initiate in 2021. C o m p l e t e d – P h a s e 1 / 2 C l i n i c a l S t u d y o f L o m e c e l - B f o r I mm u n e R e s p o n s e a n d t h e In fl u e nz a V a c cin e S ubjects W e h a v e c o m p l e t e d a P h a s e 1 / 2 mu l t i c e n t e r , r a n d o m i z e d, double - blind placebo - controlled trial designed to assess w h e t h e r a L o m e c e l - B i n f u s io n c a n i m p r o v e t h e i mmun e response in frail, elderly patients receiving the influenza vaccine. Frailty is associated with poor response to influenza vaccination and higher rates of flu due to weakened immune systems. Top line data from this trial are expected in the third quarte r o f 2 0 2 1 . E n r o ll i n g – P h a s e 1 C l i n i c a l S t u d y of Lomecel - B for Covid - 19 and Acute Re s p i r a t o r y D i s t r e s s S y n d r o m e S u b j e c t s W e a r e e n r olli n g s u b j e c t s i n o u r P h a s e 1 RE C O V E R T r i a l w h i c h i s e v a l u a t i n g L o m e c e l - B i n f u s io n s o n A c u te Respiratory Distress Syndrome (ARDS) due to COVID - 19. The RECOVER Trial is a double - blind, randomized, placebo - controlled study designed to evaluate the safety and gain preliminary information about the potential e ffi cacy of up to three intravenous administrations of Lomecel - B. The primary measures of e ffi cacy are functional lung recovery, recovery from infection, inflammatory status, immune status, and lung i m a g i n g. T h e RE C O V E R T r i a l r e c e i v e d a p r e s t i g io u s T E D C O award from the Maryland Stem Cell Research Fund (MSCRF). Participating clinical centers include the Miami VA Health System, University of Maryland Medical Center and Wake Fores t Univers it y Hospital.

H o w Doe s Lon g e v e r o n Ge t Its Bon e Mar r o w & Ma k e It s P r oduct? L o n g e v e r o n ’ s L o m e c e l - B i s a n a llo g e n e ic ( i . e . d e r i v e d f r o m a d o n o r r a t h e r t h a n f r o m o ne ’ s o w n b o d y ) m e d i c i n a l s i g n a li n g cell (MSC) isolated from donor bone marrow extractions . Bone marrow is the soft, spongy tissue inside bones. It is a reservoir for certain types of stem cells, including those that give rise to blood cells (hematopoietic stem cells), as well as t h e M S C s u s e d t o m a k e L o m e c e l - B . Why use MSCs? MSCs have a number of unique properties that make them highly attractive for their potential role in aging - related conditions and other disorders. For example, MSCs have the unique property that they do not need to be tissue - type matched, such as would be necessary for a heart or other organ transplant. MSCs express undetectable levels of a protein called major histocompatibility complex c l a s s I I ( M H C - II ) , a n d lo w l e v e l s o f M H C - I , w h i c h i s w h y M S C s can be transplanted into a host without triggering a harmful rejection response [ 1 , 2 ] . As such, MSCs that are derived from a single donor can be transplanted into unrelated patients, which is referred to as “allogeneic” use . Like all cells of the body, MSCs are subject to the damaging e ff ects of aging, and can become severely diminished in b o t h t o t a l num b e r s a n d f un c t io n w i t h a g e . T h e M S C s u s e d f o r L o m e c e l - B a r e s o u r c e d f r o m y o un g, h e a l t h y a d u l t s . T h i s is an important consideration in the context of impacting a g i n g - r e l a t e d c o n d i t io n s s i n c e t h e c e ll s o f L o m e c e l - B ar e o f a relativel y youn g phenotyp e an d les s e xpose d to detrimenta l e f f ect s o f th e agin g proces s [3] . H o w d o e s L o n g e v e r o n p i c k d o n o r s ? L o n g e v e r o n c a r e f u lly chooses donors who are extensively screened and tested for eligibility under a strict screening protocol that adheres to FDA Code of Federal Regulation (CFR) 21 Part 1271 Subpart C Donor Eligibility requirements. Potential donors undergo a comprehensive medical history and extensive laboratory testing to rule out metabolic disorders and diseases such as: bleeding and autoimmune disorders; heart, lung, or liver disease; neurological disorders; and high - risk of contracting/ transmitting communicable disease. In addition, donors are tested for numerous infectious diseases and illicit drug use (and of course, must be free of any of these). This testing occurs at several times prior to collecting bone marrow from the donor. After the donors pass the screening tests and are determined to be eligible donors, there is a bone marrow e x t r a c t io n p r o c e d u r e . T h i s s i m p l e p r o c e d u r e t a ke s j u s t minutes and requires local anesthesia and a syringe to extract marrow from the hip bone. Longeveron isolates MSCs from the fresh donated marrow, and are collected and grown in cell culture at Longeveron’s laboratory and References “How Does Longeveron Get Its Bone Marrow” 1. Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, et al. Mesenchymal stem cells for treatment of steroid - resistant, severe, acute graft - versus - host disease: a phase II study. Lancet. 2008;371(9624):1579 - 86. Epub 2008/05/13. doi: 10.1016/S0140 - 6736(08)60690 - X. PubMed PMID: 18468541. 2. Klyushnenkova E, Mosca JD, Zernetkina V, Majumdar MK, Beggs KJ, Simonetti DW, et al. T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression. J Biomed Sci. 2005;12(1):47 - 57. Epub 2005/05/03. doi: 10.1007/s11373 - 004 - 8183 - 7. PubMed PMID: 15864738. 3. Oliva AA, McClain - Moss L, Pena A, Drouillard A, Hare JM. Allogeneic mesenchymal stem cell therapy: A regenerative medicine approach to geroscience. Aging Med (Milton). 2019;2(3):142 - 6. doi: 10.1002/agm2.12079. PubMed PMID: 31667462; PubMed Central PMCID: PMCPMC6820701. manufacturing facility in Miami, Florida. The MSC cell results in a high purity product which must pass rigorous pre - defined characteristic criteria to ensure that each product adheres to the standards established by Longeveron. Once t h i s p r o c e s s i s c o m p l e t e , L o m e c e l - B i s s t o r e d i n o u r – 1 96 ƒ C deep freezers until needed, at which point the product is thawed and prepared for infusion or injection. The entire p r o d u c t io n a n d a d m i n i s t r a t io n p r o c e s s i s c o n d u c t e d according to Longeveron’s Chemistry, Manufacturing and Controls documents filed with the US FDA in our approved Investigationa l Ne w Dru g applications.

The potential of Medicinal Signaling Cells (MSCs) to impact traumatic neurological injury was recently demonstrated in a publication out of Sapporo Medical University School of Medicine and Yale University School of Medicine by Dr. Osamu Honmou, Dr. Je ff ery D. Kocsis, and colleagues [1] . They reported results from a Phase 2 clinical study using MSCs in subjects with spinal cord injury. Spinal cord injury can lead to paralysis, in which the connections between the brain and part or most of the rest of the body become permanently severed, resulting in loss of both sensation and ability to move muscles. There are currently very limited o p t io n s ( a n d n o t v e r y s u cc e ss f u l o p t io n s ) t o h e l p p r e v e n t paralysis from occurring after spinal cord injury, and to date ther e ar e n o therapie s tha t ca n revers e paralysis. The study included 13 subjects with acute spinal cord injury. E a c h r e c e i v e d a s i n g l e i n t r a v e n o u s i n f u s io n o f M S C s a t approximately 40 days after the spinal cord injury, along with receiving the regular standard of care. At six months after administration of the MSCs, 12 of the 13 subjects (92.3 %) showed improvement as assessed by the commonly used American Spinal Injury Association (ASIA) impairment scal e an d th e Internationa l S tandard s fo r Neurological and Functional Classification of Spinal Cord (ISCSCI - 92). All subjects also showed improvement in activities of daily living at six months after administration (assessed using the Spinal Cord Independence Measure, or SCIM). And just as impressively, the five patients who had a more moderate injury (Grade C on the ASIA scale) all showed improvement at just one day after MSC administration. Importantly, no MSC - related safety concerns were reported. In the study, the team used “autologous” MSCs, meaning t h e c e ll s w e r e s o u r c e d f r o m t h e s a m e s u b j e c t t o w h o m t h e y were given. The cells were then culture expanded (meaning grown outside of the body to increase their numbers). This process of cellular expansion takes about a month to complete, so as a consequence, subjects in that study were unable to receive the MSCs until approximately 26 to 54 days after the spinal cord injury. This cellular expansion process is similar to how Longeveron’s Lomecel - B product is made, but since Longeveron’s Lomecel - B is an “allogeneic” p r o d u c t ( m e a n i n g t h e c e ll s c o m e f r o m a d o n o r s o t h i s c e ll u l a r e x p a n s io n c a n b e d o n e i n a d v a n c e ) , i t c o u l d b e available and used immediately as an “o ff - the - shelf” product for spinal cord injury patients if approved by the FDA. As an interesting note, this same collaborative team had also p r e v io u s ly r e p o r t e d e n c o u r a g i n g f i n d i n g s u s i n g a u t olo g o us MSC s fo r addressin g stro k e [2] , w h i c h i s a c o n d i t io n w h e r e a blood clot can prevent blood flow to a portion of the brain. If not rapidly treated, a stroke can permanently cause cell death of the a ff ected portion of the brain and lifelong debilitating consequences. Like the spinal cord injury study, the stroke study was not placebo - controlled. Nevertheless, t h e r e w e r e i n d i c a t io n s o f p o t e n t i a l n e u r olo g i c a l improvement that suggest promise of this approach for this neurological condition, and by extension, perhaps more broadly for neurological conditions in general. Medicinal Signaling Cells – Possible Benefits for Spinal Cord Injury & Stroke R eferences “Medicinal Signaling Cell s ” 1. Honmou O, Yamashita T, Morita T, Oshigiri T, Hirota R, Iyama S, et al. Intravenous infusion of auto serum - expanded autologous mesenchymal stem cells in spinal cord injury patients: 13 case series. Clin Neurol Neurosurg. 2021;203:106565. doi: 10.1016/j. clineuro.2021.106565. PubMed PMID: 33667953. 2. Honmou O, Houkin K, Matsunaga T, Niitsu Y, Ishiai S, Onodera R, et al. Intravenous administration of auto serum - expanded autologous mesenchymal stem cells in stroke. Brain : a journal of neurology. 2011;134(Pt 6):1790 - 807. PubMed PMID: 21493695.

FORWARD - LOOKING STATEMENTS : Certain statements in this newsletter that are not historical facts are forward - looking statements that reflect management’s current expectations, assumptions, and estimates of future performance and economic conditions, and involve risks and uncertainties that could cause actual results to di f er materially from those anticipated by the statements made herein . Forward - looking statements are generally identifiable by the use of forward - looking terminology such as “believe,” “expects,” “may,” “looks to,” “will,” “should,” “plan,” “intend,” “on condition,” “target,” “see,” “potential,” “estimates,” “preliminary,” or “anticipates” or the negative thereof or comparable terminology, or by discussion of strategy or goals or other future events, circumstances, or e f ects . Moreover, forward - looking statements in this newsletter include, but are not limited to, statements about the ability of our clinical trials to demonstrate safety and e i cacy of our product candidates, and other positive results ; the timing and focus of our ongoing and future preclinical studies and clinical trials ; the size of the market opportunity for our product candidates, the beneficial characteristics, safety, e i cacy and therapeutic e f ects of our product candidates ; our ability to obtain and maintain regulatory approval of our product candidates, our plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available and our ability to avoid infringing the intellectual property rights of others . Further information relating to factors that may impact our results and forward - looking statements are disclosed in our filings with the SEC . The forward - looking statements contained in this newsletter are made as of the date of this newsletter release, and we disclaim any intention or obligation, other than imposed by law, to update or revise any forward - looking statements, whether as a result of new information, future events, or otherwise . DISCLAIMER : This Newsletter provides general information and discussion about medicine, health and related subjects . The words and other content in this Newsletter, and in any linked materials, are opinion and not intended and should not be construed as medical or legal advice or relied upon in any way . If the reader or any other person has a medical question or concern, he or she should consult with an appropriately - licensed physician or other health care worker . The views expressed in this Newsletter have no relation to those of any academic, hospital, practice or other institution with which the authors are a i liated . Life Sciences & Technology Park 1951 NW 7th A venu e, Suite 520 Miami, FL 33136 longeveron.com 1 - 833 - FOR - S TEM (1 - 833 - 367 - 7836) About Longeveron Longeveron is a clinical stage biotechnology company developing cellular therapies for specific a gi n g - r e l a t e d a n d li f e - t h r e a t e n i n g c o n d i t io n s . T h e C o m p a n y ’ s l e a d i n v e s t ig a t io n a l p r o d u c t i s th e L OMECEL - B ™ cell - base d therap y product (“ Lomecel - B ”) , whic h i s derive d fro m culture - e x p a n d e d m e d i c i n a l s ig n a li n g c e ll s ( M S C s) t h a t a r e s o u r c e d f r o m b o n e m a rr o w o f y o un g , h e a l t h y a d u l t d o n o r s . L o n g e v e r o n b e li e v e s t h a t b y u s i n g the same cells that promote tissue repair, organ m a i n t e n a n c e , a n d i mmun e s y s t e m f un c t io n , i t c a n develop safe and e ff ective therapies for some of the most di ffi cult disorders associated with the aging p r o c e s s a n d o t h e r m e d i c a l d i s o r d e r s . L o n g e v e r o n i s currentl y sponsorin g Phas e 1 an d 2 clinica l trial s in the following indications: Aging Frailty, Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). The Company’s mission is t o a d v a n c e L o m e c e l - B a n d o t h e r c e ll - b a s e d p r o d u c t c a n d i d a t e s i n t o pi v o t a l P h a s e 3 t r i a l s , w i t h t h e go a l of achieving regulatory approvals, subsequent commercialization and broad use by the healthcare community. Additional information about the Company is available at www.longeveron.com . PRS T ST D MAIL U . S . P O S T A G E PAID PERMI T NO . 2075 MIAMI , FL Lon g e v e r o n Announ c e s Pricing of an Upsized $26.6 Million Initial Public Offering & NAS D A Q Listing Longeveron Inc. (NASDAQ: LGVN ) recently became a publicly - traded company via an underwritten initial public o ff ering of the sale of 2,660,000 shares of common stock at a price of $10.00 per share and raised in the aggregate gross proceeds of $26,600,000 (prior to underwriting discounts, commissions, and other o ff ering expenses). I n a dd i t io n , a n a dd i t io n a l 25 0 , 00 0 s h a r e s w e r e p u r c h a s e d a t the public o ff ering price in connection with an overallotment option provided to the underwriters, thus raising for Longeveron an additional $2,500,000 (less the underwriting discounts and commissions). Trading of Longeveron’s common stock on the Nasdaq Capital Market under the symbol “LGVN” began on February 12, 2021. Kingswood Capital Markets, a division of Benchmark Investments, Inc., acted as sole book - runner for the o ff ering, and Alexander Capital L.P. acted as co - manager. Buchanan Ingersoll & Rooney PC acted as counsel for Longeveron, and Nelson Mullins Riley & Scarborough LLP acted as counsel to the underwriters. This newsletter shall not constitute an o f er to sell or the solicitation of an o f er to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in whic h suc h o f e r , solicitatio n o r sal e woul d b e unlawfu l prio r to registration or qualification under the securities laws of any such stat e o r jurisdiction.